Zacks Investment Research Comments on CASI Pharmaceuticals Inc’s Q3 2016 Earnings (CASI)
CASI Pharmaceuticals Inc (NASDAQ:CASI) – Stock analysts at Zacks Investment Research raised their Q3 2016 earnings estimates for shares of CASI Pharmaceuticals in a note issued to investors on Wednesday. Zacks Investment Research analyst G. Zeng now anticipates that the firm will post earnings per share of ($0.04) for the quarter, up from their previous forecast of ($0.05). Zacks Investment Research also issued estimates for CASI Pharmaceuticals’ FY2016 earnings at ($0.21) EPS, FY2017 earnings at ($0.21) EPS, FY2018 earnings at ($0.24) EPS and FY2019 earnings at ($0.16) EPS.
CASI Pharmaceuticals (NASDAQ:CASI) last announced its quarterly earnings results on Monday, August 15th. The company reported ($0.08) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.04) by $0.04.
CASI Pharmaceuticals (NASDAQ:CASI) opened at 1.08 on Monday. The stock has a 50 day moving average price of $1.13 and a 200 day moving average price of $1.17. The stock’s market capitalization is $53.41 million. CASI Pharmaceuticals has a 12 month low of $0.58 and a 12 month high of $1.82.
In related news, major shareholder Byte Ltd Sparkle purchased 3,753,855 shares of the business’s stock in a transaction that occurred on Friday, June 24th. The shares were bought at an average price of $1.19 per share, for a total transaction of $4,467,087.45. The acquisition was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
About CASI Pharmaceuticals
CASI Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the acquisition, development and commercialization of therapeutics for cancer and other medical needs. It operates through the development of targeted therapeutics for the treatment of cancer segment. Its product pipeline includes internal development of its lead drug candidate, ENMD-2076; MARQIBO, ZEVALIN and EVOMELA, and early-stage candidates in preclinical development.
Receive News & Ratings for CASI Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CASI Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.